Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vivek Subbiah

Showing results (271-280 of 487) with videos related to

Pageof 49
Sort By:
Cancer Discovery|July 6, 2022
The (R)evolution of Social Media in Oncology: Engage, Enlighten, and EncourageGilberto Morgan, Neeraj Agarwal, Toni K Choueiri, et al.
JCO Clinical Cancer Informatics|January 18, 2019
Cancer-Related Internet Use and Online Social Networking Among Patients in an Early-Phase Clinical Trials Clinic at a Comprehensive Cancer CenterGoldy C George, Adrianna Buford, Kenneth Hess, et al.
Cancers|August 23, 2020
Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and ParagangliomasCamilo Jimenez, Vivek Subbiah, Bettzy Stephen, et al.
European Journal of Cancer (Oxford, England : 1990)|August 27, 2023
Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid TumoursAlexandra Leary, Ana Oaknin, José Manuel Trigo, et al.
Journal of Gastrointestinal Cancer|April 29, 2023
Utility of Established Prognostic Scoring Systems for Patients with Advanced Pancreatic Adenocarcinoma Enrolled in Immunotherapy-Based Early-Phase Clinical TrialsRishi Surana, Graciela Nogueras Gonzalez, Jane Rogers, et al.
NPJ Precision Oncology|March 4, 2024
Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancerVivek Subbiah, Mohamed A Gouda, J Bryan Iorgulescu, et al.
Nature Reviews. Clinical Oncology|July 24, 2023
Immune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challengesGiannis Mountzios, Jordi Remon, Lizza E L Hendriks, et al.
The Oncologist|June 13, 2023
A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid TumorsBlessie Elizabeth Nelson, Apostolia M Tsimberidou, Xueyao Fu, et al.
The Oncologist|January 25, 2021
Pembrolizumab in Patients with Advanced Metastatic Germ Cell TumorsApostolia-Maria Tsimberidou, Henry Hiep Vo, Vivek Subbiah, et al.
The Lancet. Oncology|September 15, 2022
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trialVivek Subbiah, Jürgen Wolf, Bhavana Konda, et al.
Pageof 49

Showing results (271-280 of 487) with videos related to

Sort By:
Pageof 49
Cancer Discovery|July 6, 2022
The (R)evolution of Social Media in Oncology: Engage, Enlighten, and EncourageGilberto Morgan, Neeraj Agarwal, Toni K Choueiri, et al.
JCO Clinical Cancer Informatics|January 18, 2019
Cancer-Related Internet Use and Online Social Networking Among Patients in an Early-Phase Clinical Trials Clinic at a Comprehensive Cancer CenterGoldy C George, Adrianna Buford, Kenneth Hess, et al.
Cancers|August 23, 2020
Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and ParagangliomasCamilo Jimenez, Vivek Subbiah, Bettzy Stephen, et al.
European Journal of Cancer (Oxford, England : 1990)|August 27, 2023
Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid TumoursAlexandra Leary, Ana Oaknin, José Manuel Trigo, et al.
Journal of Gastrointestinal Cancer|April 29, 2023
Utility of Established Prognostic Scoring Systems for Patients with Advanced Pancreatic Adenocarcinoma Enrolled in Immunotherapy-Based Early-Phase Clinical TrialsRishi Surana, Graciela Nogueras Gonzalez, Jane Rogers, et al.
NPJ Precision Oncology|March 4, 2024
Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancerVivek Subbiah, Mohamed A Gouda, J Bryan Iorgulescu, et al.
Nature Reviews. Clinical Oncology|July 24, 2023
Immune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challengesGiannis Mountzios, Jordi Remon, Lizza E L Hendriks, et al.
The Oncologist|June 13, 2023
A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid TumorsBlessie Elizabeth Nelson, Apostolia M Tsimberidou, Xueyao Fu, et al.
The Oncologist|January 25, 2021
Pembrolizumab in Patients with Advanced Metastatic Germ Cell TumorsApostolia-Maria Tsimberidou, Henry Hiep Vo, Vivek Subbiah, et al.
The Lancet. Oncology|September 15, 2022
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trialVivek Subbiah, Jürgen Wolf, Bhavana Konda, et al.
Pageof 49